Lars Christian Lund

Medicine & Life Sciences

1. Cohort Studies 100%
2. Coronavirus 85%
3. SARS Virus 73%
4. Severe Acute Respiratory Syndrome 65%
5. Denmark 52%
6. Population 47%
7. Idiopathic Pulmonary Fibrosis 40%
8. Gout 40%
9. Venous Thromboembolism 38%
10. Human Influenza 36%
11. Odds Ratio 35%
12. Dicloxacillin 35%
13. Angiotensin Receptor Antagonists 34%
14. Prescriptions 29%
15. Serotonin Uptake Inhibitors 27%
16. Pharmaceutical Preparations 27%
17. Mortality 27%
18. Febuxostat 27%
19. Floxacillin 26%
20. Anti-Inflammatory Agents 26%
21. Glucagon-Like Peptide-1 Receptor 25%
22. Thioridazine 24%
23. Intensive Care Units 24%
24. Sodium-Glucose Transport Proteins 24%
25. Confidence Intervals 24%
26. Lactulose 23%
27. Scandinavian and Nordic Countries 22%
28. Equivalence Trials 22%
29. Dipeptidyl-Peptidase IV Inhibitors 22%
30. Propensity Score 22%
31. Restless Legs Syndrome 22%
32. Quetiapine Fumarate 22%
33. Nephrolithiasis 22%
34. Hemorrhage 21%
35. Angiotensin-Converting Enzyme Inhibitors 21%
36. Hospitalization 21%
37. Allopurinol 21%
38. Registries 20%
39. Troponin I 20%
40. Drug Therapy 19%
41. Heart Valves 19%
42. Pneumonia 19%
43. Viscera 18%
44. Polymerase Chain Reaction 18%
45. Norway 18%
46. Morbidity 18%
47. Warfarin 17%
48. Renin-Angiotensin System 17%
49. Infections 17%
50. Blood Culture 17%